Helen Knight
Tracked across 1 events · 7 articles · First seen Mar 31, 2026 · Last active Apr 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Helen Knight, director of medicines evaluation at United Kingdom — National Institute for Health and Care Research, commented on the compelling evidence from clinical trials supporting semaglutide's effectiveness.
Mar 31, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Helen Knight live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard